QR678® Expands East Asia Presence With Malaysia Approval for QR678 PREO®, QR678 NEO® and QR678 ZEO® regenerative hair products.

▴ QR 678® ZEO®
QR678®, a patented, global, scalp science and regenerative hair regeneration research platform focused on structured biological signalling approaches in hair and scalp wellness, has received product approvals in Malaysia for QR678 PREO®, QR678 NEO® and QR678 ZEO®.

Kuala Lumpur, 15th June, 2026: QR678®, a patented, global, scalp science and regenerative hair regeneration research platform focused on structured biological signalling approaches in hair and scalp wellness, has received product approvals in Malaysia for QR678 PREO®, QR678 NEO® and QR678 ZEO®. The approvals mark a significant milestone in the international expansion of products derived from QR678® and reinforce the growing global relevance of Indian-origin innovation in cosmetic science and biologically informed aesthetic care.

The notification, issued under Malaysia’s Control of Drugs and Cosmetics Regulations by the Ministry of Health Malaysia, allows QR678 PREO®, QR678 NEO® and QR678 ZEO® to be introduced in Malaysia in line with local cosmetic product requirements. The development creates a formal pathway for QR678® to collaborate with Malaysian distributors and for QR678® products to be used for patients at dermatology practices, aesthetic clinics and wellness partners across Malaysia, as the QR678® brand expands across Asia.

Unlike conventional product-led portfolios, QR678 PREO®, QR678 NEO® and QR678 ZEO® have been developed as distinct hair products derived from the broader USA and globally patented QR678® hair regenerative research ecosystem.

Each product is built around a specific formulation philosophy designed to support structured biological signalling and protocol-driven application. QR678 PREO® focuses on precision and reproducibility, QR678 NEO® on network organisation, and QR678 ZEO® on pathway orchestration. Together, they reflect the QR678® brand’s long-term focus on creating standardised and structured formulation environments designed around consistency, biological organisation and clinician-guided use.

Developed through more than 18 years of research and clinical innovation, the QR678® research platform has evolved from an Indian research initiative into a globally patented, expanding platform in hair biology and regenerative aesthetics. Its various proprietary formulations are currently trusted by over 5,000 dermatologists, aesthetic physicians and hair restoration specialists across more than 2,000 clinics in over 10 countries, and have reached more than 150,000 patients globally. The company has applied for 5 more global patents in 2025, in addition to its existing patents.

The global hair restoration market is projected to reach USD 8.71 billion in 2026, with Asia-Pacific emerging as one of the fastest-growing regions for aesthetic and wellness solutions. Against this backdrop, Malaysia represents an important gateway market for QR678®, given its established aesthetic medicine ecosystem, growing demand for evidence-led cosmetic care and increasing adoption of practitioner-guided approaches across the region.

The approvals also reflect the broader emergence of India as a source of innovation in medical aesthetics, cosmetic science and regenerative hair research. As international markets increasingly seek structured, reproducible and protocol-based solutions, patented research and development platforms are playing a more visible role in shaping the future of innovative aesthetic care. QR678®’s expansion into Malaysia represents another step in taking patented innovations to global doctor communities.

“Malaysia represents an important milestone for QR678®, but the larger significance lies in the continued global acceptance of structured and scientifically developed platform approaches within hair biology and aesthetic medicine. QR678 PREO®, QR678 NEO® and QR678 ZEO® represent state-of-the-art hair products built around precision, reproducibility, network organisation and pathway orchestration. These concepts are rooted in our broader philosophy of creating patented, science and evidence based, structured biological signalling environments that support consistent results and protocol-driven application.

Across international markets, clinicians are increasingly seeking scientifically designed formulations that move beyond variability and emphasise standardisation, reproducibility and biologically informed design. The approvals in Malaysia create an opportunity to expand access to QR678 PREO®, QR678 NEO® and QR678 ZEO® through commercial partnerships while continuing to demonstrate how patented research and development can contribute meaningfully to global advances in cosmetic science and regenerative aesthetics. We are excited to bring the patented products to Malaysian Doctors and patients,” said Dr Khushbu Jamasbi, Senior Manager, QR678®, Malaysia.

As QR678® continues to expand internationally, the company remains focused on strengthening partnerships with medical professionals, distributors and wellness experts across key markets. The Malaysia approvals are expected to support wider accessibility, regional collaborations and future growth opportunities across Southeast Asia while reinforcing QR678®’s position as a globally expanding research and development platform.

Tags : #

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Digital Identity Fraud in Healthcare: What India Must KnowNovember 18, 2026
Wearables in Clinical Care: When Should Doctors Trust the Data?November 18, 2026
Cybersecurity for Medical Startups: What Founders MissNovember 18, 2026
Remote Patient Monitoring: The Next Phase of Virtual CareNovember 18, 2026
Digital Health Wallets: Future of Medical Records in IndiaNovember 17, 2026
How Hospitals Can Prepare for a Transparent Healthcare MarketNovember 17, 2026
Childhood Nutrition: Understanding Micronutrient Gaps Beyond CaloriesNovember 16, 2026
Anaemia in Adolescent Girls: Connecting Prevention, Testing and Nutrition SupportNovember 16, 2026
Health Information Exchanges in India: Are Medical Records Finally Going Portable?November 16, 2026
Hospital Accreditation in 2026: What Is Changing Beyond the Checklist?November 16, 2026
Digital Insurance Platforms and India's Health Coverage FutureNovember 14, 2026
ABDM 2.0: India's Digital Health Ecosystem FutureNovember 14, 2026
Vaccine Cold-Chain Management: Protecting Immunisation Quality From Storage to DeliveryNovember 14, 2026
Foodborne Illness Surveillance: How Public Health Systems Track RisksNovember 14, 2026
Interoperability in Indian Healthcare: Why Patient Data Still StrugglesNovember 13, 2026
Tuberculosis Contact Screening: How Preventive Care Works Around ExposureNovember 13, 2026
COPD Care in India: Linking Diagnosis, Inhaler Education and Follow-UpNovember 13, 2026
Management of ANCA Glomerulonephritis: Induction & Maintenance ProtocolsNovember 12, 2026
Smart Hospital Command Centres Transforming IndiaNovember 12, 2026
Gamma Knife Surgery in India: What You Need to KnowNovember 12, 2026